127 related articles for article (PubMed ID: 19960500)
1. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype.
Murphy T; Darby S; Mathers ME; Gnanapragasam VJ
J Pathol; 2010 Mar; 220(4):452-60. PubMed ID: 19960500
[TBL] [Abstract][Full Text] [Related]
2. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
3. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
7. A role for extracellular and transmembrane domains of Sef in Sef-mediated inhibition of FGF signaling.
Kovalenko D; Yang X; Chen PY; Nadeau RJ; Zubanova O; Pigeon K; Friesel R
Cell Signal; 2006 Nov; 18(11):1958-66. PubMed ID: 16603339
[TBL] [Abstract][Full Text] [Related]
8. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
[TBL] [Abstract][Full Text] [Related]
9. Identification of Sef, a novel modulator of FGF signalling.
Tsang M; Friesel R; Kudoh T; Dawid IB
Nat Cell Biol; 2002 Feb; 4(2):165-9. PubMed ID: 11802164
[TBL] [Abstract][Full Text] [Related]
10. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer.
Kwabi-Addo B; Wang J; Erdem H; Vaid A; Castro P; Ayala G; Ittmann M
Cancer Res; 2004 Jul; 64(14):4728-35. PubMed ID: 15256439
[TBL] [Abstract][Full Text] [Related]
11. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.
Chaffer CL; Dopheide B; Savagner P; Thompson EW; Williams ED
Differentiation; 2007 Nov; 75(9):831-42. PubMed ID: 17697126
[TBL] [Abstract][Full Text] [Related]
12. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2.
Shain SA
Mol Cancer Res; 2004 Nov; 2(11):653-61. PubMed ID: 15561781
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
Udayakumar TS; Nagle RB; Bowden GT
Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
[TBL] [Abstract][Full Text] [Related]
14. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
15. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
17. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease.
Dorkin TJ; Robinson MC; Marsh C; Bjartell A; Neal DE; Leung HY
Oncogene; 1999 Apr; 18(17):2755-61. PubMed ID: 10348350
[TBL] [Abstract][Full Text] [Related]
18. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells.
Antoine M; Wirz W; Tag CG; Mavituna M; Emans N; Korff T; Stoldt V; Gressner AM; Kiefer P
Growth Factors; 2005 Jun; 23(2):87-95. PubMed ID: 16019430
[TBL] [Abstract][Full Text] [Related]
19. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells.
Ruohola JK; Viitanen TP; Valve EM; Seppänen JA; Loponen NT; Keskitalo JJ; Lakkakorpi PT; Härkönen PL
Cancer Res; 2001 May; 61(10):4229-37. PubMed ID: 11358849
[TBL] [Abstract][Full Text] [Related]
20. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
